Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009-2011

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 5, 2013, Pages 624-629

  Gegia, M ^a   Jenkins, H E ^b,c   Kalandadze, I ^d   Furin, Jennifer ^e  

^a UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Georgia   (Georgia)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Georgia; Multidrug resistant TB; Pediatrics

Indexed keywords

AMINOSALICYLIC ACID; CAPREOMYCIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GEORGIA (REPUBLIC); HUMAN; INFANT; MALE; MEDICAL RECORD REVIEW; MULTIDRUG RESISTANT TUBERCULOSIS; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS CONTROL;

ADOLESCENT; AGE FACTORS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GEORGIA (REPUBLIC); HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84876826261     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0792     Document Type: Article

References (25)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. World Health Organization. Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015. WHO/HTM/TB/2011.3. Geneva, Switzerland: WHO, 2011.
3. Perez-Velez C M. Pediatric tuberculosis: new guidelines and recommendations. Curr Opin Pediatr 2012; 24: 319-328.
4. Swaminathan S, Rekha B. Pediatric tuberculosis: global overview and challenges. Clin Infect Dis 2010; 50 (Suppl 3): S184-S194.
5. Seddon J A, Hesseling A C, Willemse M, Donald P R, Schaaf H S. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcomes. Clin Infect Dis 2012; 54: 157-166.
6. Schaaf H S. Drug-resistant tuberculosis in children. S Afr Med J 2007; 97: 995-997. (Pubitemid 350027957)
7. Marais B J, Schaaf H S, Donald P R. Management of tuberculosis in children and new treatment options. Infect Disord Drug Targets 2011; 11: 144-156.
8. Ettehad D, Schaaf H S, Seddon J A, Cooke G S, Ford N. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
9. Drobac P C, Mukherjee J S, Joseph J K, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics 2006; 117: 2022-2029. (Pubitemid 46071247)
10. Mendez Echevarria A, Baquero Artigao F, Garcia Miguel M J, et al. Multidrug-resistant tuberculosis in the pediatric age group. An Pediatr (Barc) 2007; 67: 206-211. (Pubitemid 47394852)
11. Bonnet M, Pardini M, Meacci F, et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS ONE 2011; 6: e23081.
12. National Center for Tuberculosis and Lung Diseases. TB in Georgia, 2011. National TB Program, Tblisi, Georgia: National Center for Tuberculosis and Lung Diseases, 2011. http://www.tbgeo.ge/index.php?a=page&lang=en&pid=154 Accessed January 2013.
13. Lomtadze N, Aspindzelashvili R, Janjgava M, et al. Prevalence and risk factors for multidrug-resistant tuberculosis in the Republic of Georgia: a population-based study. Int J Tuberc Lung Dis 2009; 13: 68-73.
14. Furin J, Gegia M, Mitnick C, et al. Eliminating the category II retreatment regimen from national tuberculosis programme guidelines: the Georgian experience. Bull World Health Organ 2012; 90: 63-66.
15. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. WHO/HTM/TB/2011.6. Geneva, Switzerland: WHO, 2011.
16. World Health Organization. Rapid advice: treatment of tuberculosis in children. WHO/HTM/TB/2010.13. Geneva, Switzerland: WHO, 2010.
17. Drobniewski F A, Hoffner S, Rüsch-Gerdes S, Skenders G, Thomsen V, and the WHO European Laboratory Strengthening Task Force. Recommended standards for modern tuberculosis laboratory services in Europe. Eur Respir J 2006; 5: 903-909. (Pubitemid 46331956)
18. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf Accessed January 2013.
19. Agresti A, Coull B A. Approximate is better than 'exact' for interval estimation of binomial proportions. Am Stat 1998; 52: 119-126.
20. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/ 2008.402. Geneva, Switzerland: WHO, 2008.
21. Leimane V. Treatment and management of MDR-TB in Latvia. Bull World Health Organ 2007; 85: 393-394. (Pubitemid 46718370)
22. Vashakidze L, Salakaia A, Shubladze N, et al. Prevalence and risk factors for drug resistance among hospitalized tuberculosis patients in Georgia. Int J Tuberc Lung Dis 2009; 13: 1148-1153.
23. Shin S S, Pasechnikov A D, Gelmanova I Y, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis 2007; 11: 1314-1320.
24. Furin J J, Mitnick C D, Shin S S, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001; 5: 648-655. (Pubitemid 32652155)
25. Gegia M, Kalandadze I, Kempker R R, Magee M J, Blumberg H M. Adjunctive surgery improves treatment outcomes among patients with multidrug-resistant and extensively drug-resistant tuberculosis. Int J Infect Dis 2012; 16: e391-396.